Literature DB >> 26663202

Cloning, characterization, and production of three α-L-fucosidases from Clostridium perfringens ATCC 13124.

Shuquan Fan1, Huaqin Zhang1, Xiaodi Chen1, Lili Lu1, Li Xu1, Min Xiao1.   

Abstract

α-L-Fucosidases are key enzymes for the degradation of intestinal glycans by gut microbes. In this work, three putative α-L-fucosidases (Afc1, Afc2, and Afc3) genes from Clostridium perfringens ATCC 13124 were cloned and expressed in Escherichia coli. Afc1 had the α-L-fucosidase domain of glycoside hydrolase (GH) 29 family but showed no enzyme activity toward all the substrates examined. The putative acid/base residue of Afc1, Ser205, was replaced by a glutamic acid which is conserved in GH29-B α-L-fucosidases. However, the mutant Afc1-S205E still failed to show enzyme activity. Afc2 and Afc3 were determined to be 1,3-1,4-α-L-fucosidase of GH29-B subfamily and 1,2-α-L-fucosidase of GH95 family, respectively, and both of them could release fucose from porcine gastric mucin (PGM). When C. perfringens ATCC 13124 grew with the presence of PGM, the transcription of afc1 decreased slightly, while those of afc2 and afc3 increased to 2.2-fold and 1.4-fold, respectively, and the enzyme activities of Afc2 and Afc3 in the culture increased to 2.2-fold and 2.6-fold, respectively. These results suggest that Afc2 and Afc3 are involved in the degradation of intestinal fucosyl glycans by C. perfringens ATCC 13124.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  1,2-α-l-fucosidase; 1,3-1,4-α-l-fucosidase; Clostridium perfringens; Fucosyloligosaccharides; Mucin O-glycans

Mesh:

Substances:

Year:  2015        PMID: 26663202     DOI: 10.1002/jobm.201500582

Source DB:  PubMed          Journal:  J Basic Microbiol        ISSN: 0233-111X            Impact factor:   2.281


  6 in total

1.  Adaptation of Syntenic Xyloglucan Utilization Loci of Human Gut Bacteroidetes to Polysaccharide Side Chain Diversity.

Authors:  Guillaume Déjean; Alexandra S Tauzin; Stuart W Bennett; A Louise Creagh; Harry Brumer
Journal:  Appl Environ Microbiol       Date:  2019-10-01       Impact factor: 4.792

2.  Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.

Authors:  John A McCulloch; Diwakar Davar; Richard R Rodrigues; Jonathan H Badger; Jennifer R Fang; Alicia M Cole; Ascharya K Balaji; Marie Vetizou; Stephanie M Prescott; Miriam R Fernandes; Raquel G F Costa; Wuxing Yuan; Rosalba Salcedo; Erol Bahadiroglu; Soumen Roy; Richelle N DeBlasio; Robert M Morrison; Joe-Marc Chauvin; Quanquan Ding; Bochra Zidi; Ava Lowin; Saranya Chakka; Wentao Gao; Ornella Pagliano; Scarlett J Ernst; Amy Rose; Nolan K Newman; Andrey Morgun; Hassane M Zarour; Giorgio Trinchieri; Amiran K Dzutsev
Journal:  Nat Med       Date:  2022-02-28       Impact factor: 87.241

3.  Identification and characterization of a core fucosidase from the bacterium Elizabethkingia meningoseptica.

Authors:  Tiansheng Li; Mengjie Li; Linlin Hou; Yameng Guo; Lei Wang; Guiqin Sun; Li Chen
Journal:  J Biol Chem       Date:  2017-12-01       Impact factor: 5.157

Review 4.  Rethinking the role of alpha toxin in Clostridium perfringens-associated enteric diseases: a review on bovine necro-haemorrhagic enteritis.

Authors:  Evy Goossens; Bonnie R Valgaeren; Bart Pardon; Freddy Haesebrouck; Richard Ducatelle; Piet R Deprez; Filip Van Immerseel
Journal:  Vet Res       Date:  2017-02-16       Impact factor: 3.683

5.  Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.

Authors:  Eva M Moya-Gonzálvez; Nazaret Peña-Gil; Antonio Rubio-Del-Campo; José M Coll-Marqués; Roberto Gozalbo-Rovira; Vicente Monedero; Jesús Rodríguez-Díaz; María J Yebra
Journal:  Microbiol Spectr       Date:  2022-08-09

6.  Metabolism of the predominant human milk oligosaccharide fucosyllactose by an infant gut commensal.

Authors:  Kieran James; Francesca Bottacini; Jose Ivan Serrano Contreras; Mariane Vigoureux; Muireann Egan; Mary O'connell Motherway; Elaine Holmes; Douwe van Sinderen
Journal:  Sci Rep       Date:  2019-10-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.